DE60325347D1 - Substituierte chinoloncarbonsäuren, ihre derivate, wirkungsort und anwendungen - Google Patents

Substituierte chinoloncarbonsäuren, ihre derivate, wirkungsort und anwendungen

Info

Publication number
DE60325347D1
DE60325347D1 DE60325347T DE60325347T DE60325347D1 DE 60325347 D1 DE60325347 D1 DE 60325347D1 DE 60325347 T DE60325347 T DE 60325347T DE 60325347 T DE60325347 T DE 60325347T DE 60325347 D1 DE60325347 D1 DE 60325347D1
Authority
DE
Germany
Prior art keywords
derivatives
sub
substituted
acids
chinoloncarboxylic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60325347T
Other languages
German (de)
English (en)
Inventor
Timothy B C Johnstone
Derk J Hogenkamp
Kelvin W Gee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Application granted granted Critical
Publication of DE60325347D1 publication Critical patent/DE60325347D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
DE60325347T 2002-05-14 2003-05-12 Substituierte chinoloncarbonsäuren, ihre derivate, wirkungsort und anwendungen Expired - Lifetime DE60325347D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38064102P 2002-05-14 2002-05-14
PCT/US2003/014948 WO2003097564A2 (en) 2002-05-14 2003-05-12 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof

Publications (1)

Publication Number Publication Date
DE60325347D1 true DE60325347D1 (de) 2009-01-29

Family

ID=29549994

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60325347T Expired - Lifetime DE60325347D1 (de) 2002-05-14 2003-05-12 Substituierte chinoloncarbonsäuren, ihre derivate, wirkungsort und anwendungen

Country Status (16)

Country Link
US (2) US7355047B2 (cg-RX-API-DMAC7.html)
EP (1) EP1503759B1 (cg-RX-API-DMAC7.html)
JP (1) JP4532263B2 (cg-RX-API-DMAC7.html)
KR (1) KR20040107525A (cg-RX-API-DMAC7.html)
CN (1) CN1652784A (cg-RX-API-DMAC7.html)
AT (1) ATE417613T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003229043B2 (cg-RX-API-DMAC7.html)
BR (1) BR0309965A (cg-RX-API-DMAC7.html)
CA (1) CA2484308A1 (cg-RX-API-DMAC7.html)
DE (1) DE60325347D1 (cg-RX-API-DMAC7.html)
DK (1) DK1503759T3 (cg-RX-API-DMAC7.html)
ES (1) ES2319176T3 (cg-RX-API-DMAC7.html)
IL (1) IL164734A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04011156A (cg-RX-API-DMAC7.html)
NZ (1) NZ536061A (cg-RX-API-DMAC7.html)
WO (1) WO2003097564A2 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040107525A (ko) * 2002-05-14 2004-12-20 더 리전트 오브 더 유니버시티 오브 캘리포니아 치환된 퀴놀론 카르복실산, 이들의 유도체, 그의 작용부위 및 용도
US7470706B2 (en) 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
DE102004004971B3 (de) * 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel
AU2005240657A1 (en) * 2004-05-06 2005-11-17 The Regents Of The University Of California Substituted enaminones, their derivatives and uses thereof
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
BR122018075478B8 (pt) 2004-06-24 2023-10-31 Vertex Pharma moduladores de transportadores de cassete de ligação de atp
JP4796622B2 (ja) * 2005-04-11 2011-10-19 エフ．ホフマン−ラ ロシュ アーゲー （３，４−ジヒドロ−キナゾリン−２−イル）−インダン−１−イル−アミン
AU2006243244A1 (en) * 2005-05-04 2006-11-09 F. Hoffmann-La Roche Ag (3,4-dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amines having an activity on the 5-HT receptor
AU2006322045A1 (en) * 2005-12-05 2007-06-14 Merck & Co., Inc. Quinolone M1 receptor positive allosteric modulators
EP1979367A2 (en) * 2005-12-24 2008-10-15 Vertex Pharmaceuticals Incorporated Quinolin-4-one derivatives as modulators of abc transporters
HUE032813T2 (en) 2005-12-28 2017-11-28 Vertex Pharma Solid forms of N- [2,4-bis (1,1-dimethyl ethyl) -5-hydroxyphenyl] -1,4-dihydro-4-oxoquinoline-3-carboxamide
EP2013182B1 (en) * 2006-03-13 2013-09-04 Kyorin Pharmaceutical Co., Ltd. Aminoquinolones as gsk-3 inhibitors
CA2660421A1 (en) * 2006-08-10 2008-02-14 Ferrer Internacional S.A. 1h-quinolin-4-one compounds, with affinity for the gaba receptor, processes, uses and compositions
EP1886996A1 (en) * 2006-08-10 2008-02-13 Ferrer Internacional, S.A. 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
NZ576036A (en) 2006-10-16 2010-10-29 Bionomics Ltd Naphthyridine containing compounds for treating anxiety disorders
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
WO2009040377A2 (en) * 2007-09-27 2009-04-02 Ge Healthcare Limited Imaging agents
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
JP2012506857A (ja) * 2008-10-23 2012-03-22 メルク・シャープ・エンド・ドーム・コーポレイション 縮合複素環式ｍ１受容体ポジティブアロステリック調節因子
HUE035160T2 (en) 2009-03-20 2018-05-02 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
US20120093917A1 (en) * 2009-04-02 2012-04-19 Robert Hromas Metnase and intnase inhibitors and their use in treating cancer
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
CA2828780A1 (en) 2011-03-02 2012-09-07 Bionomics Limited Novel small-molecules as therapeutics
AU2012222869B2 (en) * 2011-03-02 2015-08-13 Bionomics Limited Methods of treating a disease or condition of the central nervous system
US9133188B2 (en) 2011-05-12 2015-09-15 Bionomics Limited Methods for preparing naphthyridines
CA2865519C (en) 2012-02-27 2018-01-02 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl0-5-hydroxyphenyl-1]-1,4-dihydro-4-oxoquinolone-3-carboxamide for treating cystic fibrosis
EP3204358B1 (en) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CN107501107A (zh) * 2017-09-26 2017-12-22 兰亚朝 喹诺酮药物的中间体合成方法
CN111269131B (zh) * 2020-03-12 2021-12-28 江苏飞宇医药科技股份有限公司 以三正丙胺为吸酸剂制备环丙乙酯胺化物的工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1433774A (en) * 1973-02-26 1976-04-28 Allen & Hanburys Ltd Heterocyclic compounds apparatus for conveying articles
JPS5715760B2 (cg-RX-API-DMAC7.html) * 1974-06-11 1982-04-01
US4390541A (en) 1980-12-19 1983-06-28 Lilly Industries Limited Quinolone derivatives and their use in a method of controlling an immediate hypersensitivity disease
US6248739B1 (en) * 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
US6413956B1 (en) * 1999-05-06 2002-07-02 Neurogen Corporation Substituted 4-oxo-quinoline-3-carboxamides
GB0127349D0 (en) * 2001-11-14 2002-01-02 Glaxo Group Ltd Macrolides
KR20040107525A (ko) * 2002-05-14 2004-12-20 더 리전트 오브 더 유니버시티 오브 캘리포니아 치환된 퀴놀론 카르복실산, 이들의 유도체, 그의 작용부위 및 용도

Also Published As

Publication number Publication date
BR0309965A (pt) 2005-03-01
US7355047B2 (en) 2008-04-08
EP1503759A2 (en) 2005-02-09
CA2484308A1 (en) 2003-11-27
US20080176897A1 (en) 2008-07-24
HK1072905A1 (en) 2005-09-16
IL164734A0 (en) 2005-12-18
ATE417613T1 (de) 2009-01-15
CN1652784A (zh) 2005-08-10
AU2003229043A1 (en) 2003-12-02
EP1503759B1 (en) 2008-12-17
JP2005535592A (ja) 2005-11-24
AU2003229043B2 (en) 2008-12-04
KR20040107525A (ko) 2004-12-20
MXPA04011156A (es) 2005-02-17
NZ536061A (en) 2008-09-26
DK1503759T3 (da) 2009-04-14
JP4532263B2 (ja) 2010-08-25
WO2003097564A3 (en) 2004-02-26
EP1503759A4 (en) 2006-02-15
ES2319176T3 (es) 2009-05-05
WO2003097564A2 (en) 2003-11-27
US20060178516A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
DE60325347D1 (de) Substituierte chinoloncarbonsäuren, ihre derivate, wirkungsort und anwendungen
EP1391201A4 (en) MEDICAL COMPOSITIONS
DE60215652D1 (de) Aromatische hydroxamsäurederivate, die sich als hdac inhibitoren eignen
DE602005013417D1 (de) (biphenyl)carbonsäuren und derivate davon
MX2007003335A (es) Acidos aceticos de bencimidazol que muestran antagonismo de receptor crth2 y usos de los mismos.
EP2234963A4 (en) LEVODOPA FORMULATIONS WITH CONTROLLED RELEASE AND ITS USE
CY1108011T1 (el) Συνδυασμος παρεμποδιστου nsaid και pde4
DK1641764T3 (da) P38-kinasehæmmere på grundlag af 5-leddede heterocykliske forbindelser
EA200100958A1 (ru) Производные 4,5-диарил-3(2h)-фуранона как ингибиторы циклооксигеназы-2
EA200970190A1 (ru) Соединения индола
DE69912581D1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
DK1311256T3 (da) Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser
WO2006036994A3 (en) Modulators of crth2, cox-2 and faah
UY27618A1 (es) Ésteres hidroxamato de ácido n-(4-fenil-sustituido)-antranílico
DK0966424T3 (da) Aminobenzophenoner som inhibitorer for interleukin og TNF
NO20056161L (no) Formuleringer for behandling av artrittilstander
DE60216641D1 (de) Polymorph von 4-ä2-ä4-ä1-(2-ethoxyethyl)-1h-benzimidazol-2-ylü-1-piperidinylüethylü-alpha, alpha-dimethylbenzolessigsäure
DE50305117D1 (de) Essig- und propionsäureamide
UA85711C2 (ru) Замещенные енаминоны, их производные и их применение
ITMC20010029U1 (it) Placca chirurgica anti-trauma per il fissaggio di monconi mandibiolari
ATE466858T1 (de) 3-arylisoxazol-4-carbonylbenzofuranderivative
ATE402153T1 (de) Chirale oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten
ITMI20020986A1 (it) Composizione a base di diclofenac per il trattamento topico di affezioni del cavo orofaringeo
DE60216083D1 (de) (OXOPYRAZOLOi1,5AöPYRIMIDIN-2-YL) ALKYLCARBONSÄUREAMIDE
MY145122A (en) Phenylacetic acid derivatives as cox-2 inhibitors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition